ES2600355T3 - Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis - Google Patents
Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis Download PDFInfo
- Publication number
- ES2600355T3 ES2600355T3 ES11744440.6T ES11744440T ES2600355T3 ES 2600355 T3 ES2600355 T3 ES 2600355T3 ES 11744440 T ES11744440 T ES 11744440T ES 2600355 T3 ES2600355 T3 ES 2600355T3
- Authority
- ES
- Spain
- Prior art keywords
- psoriasis
- contact dermatitis
- allergic contact
- treatment
- receptor antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012442 Dermatitis contact Diseases 0.000 title abstract 2
- 201000004681 Psoriasis Diseases 0.000 title abstract 2
- 208000002029 allergic contact dermatitis Diseases 0.000 title abstract 2
- 101150109738 Ptger4 gene Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 4- {2-ethyl-4,6- dimethyl-1Himidazo [4,5-c] pyridin-1-yl} phenyl Chemical group 0.000 abstract 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28250610P | 2010-02-22 | 2010-02-22 | |
| US282506P | 2010-02-22 | ||
| PCT/JP2011/000994 WO2011102149A1 (en) | 2010-02-22 | 2011-02-22 | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2600355T3 true ES2600355T3 (es) | 2017-02-08 |
Family
ID=44482754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11744440.6T Active ES2600355T3 (es) | 2010-02-22 | 2011-02-22 | Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9457084B2 (enExample) |
| EP (1) | EP2538978B1 (enExample) |
| JP (2) | JP6152643B2 (enExample) |
| KR (1) | KR101780666B1 (enExample) |
| CN (2) | CN107693518A (enExample) |
| BR (1) | BR112012020236A2 (enExample) |
| CA (2) | CA3009937C (enExample) |
| ES (1) | ES2600355T3 (enExample) |
| HK (1) | HK1249401A1 (enExample) |
| MX (1) | MX341482B (enExample) |
| RU (1) | RU2571816C2 (enExample) |
| WO (1) | WO2011102149A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3296B1 (ar) | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| WO2015094902A1 (en) | 2013-12-17 | 2015-06-25 | Eli Lilly And Company | Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators |
| TW201607943A (zh) * | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| TWI664969B (zh) | 2014-03-06 | 2019-07-11 | 雅瑞塔那醫療公司 | 格拉匹綸(ｇｒａｐｉｐｒａｎｔ)組合物及其使用方法 |
| WO2017066633A1 (en) * | 2015-10-16 | 2017-04-20 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
| US10342785B2 (en) * | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| CA3047336A1 (en) | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| CN109836434B (zh) * | 2017-11-27 | 2020-09-25 | 上海宇耀生物科技有限公司 | 噻吩并环类化合物及其合成方法和应用 |
| JP2021522211A (ja) | 2018-04-16 | 2021-08-30 | アリーズ セラピューティクス， インコーポレイテッド | Ｅｐ４阻害剤およびその使用 |
| WO2019245590A1 (en) | 2018-06-18 | 2019-12-26 | Avista Pharma Solutions, Inc. | Chemical compounds |
| EP3820480A4 (en) | 2018-07-11 | 2022-03-09 | Arrys Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND USES THEREOF |
| AU2019306658A1 (en) | 2018-07-20 | 2021-01-07 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| EP3823726A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche SA | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| RS65335B1 (sr) | 2018-10-05 | 2024-04-30 | Annapurna Bio Inc | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj |
| CA3128346A1 (en) | 2019-01-30 | 2020-08-06 | Avista Pharma Solutions, Inc. | Synthetic process and novel intermediates |
| MX2021009082A (es) | 2019-01-30 | 2021-09-08 | Avista Pharma Solutions Inc | Compuestos quimicos. |
| CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| MXPA04009243A (es) * | 2002-04-12 | 2005-06-08 | Pfizer | Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6. |
| ATE396182T1 (de) * | 2003-01-29 | 2008-06-15 | Asterand Uk Ltd | Hemmstoffe des ep4-rezeptors |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| EP1663979B1 (en) * | 2003-09-03 | 2013-10-09 | RaQualia Pharma Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| US20090036495A1 (en) * | 2004-04-20 | 2009-02-05 | Pfizer, Inc. | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists |
| AP2006003785A0 (en) | 2004-05-04 | 2006-10-31 | Pfizer | Substituted methylaryl or heteroaryl amide compounds |
| MX2007011110A (es) * | 2005-03-11 | 2008-02-21 | Pfizer | Formas de cristal de un derivado de imidazol. |
| EP1886987A1 (en) * | 2006-08-11 | 2008-02-13 | Givaudan S.A. | Process for producing 2,2,3-trimethylcyclopent-3-enecarbaldehyde (campholytic aldehyde) |
| CN101541778B (zh) * | 2006-08-11 | 2014-10-08 | 默克加拿大有限公司 | 作为ep4受体配体的噻吩甲酰胺衍生物 |
-
2011
- 2011-02-22 BR BR112012020236A patent/BR112012020236A2/pt not_active Application Discontinuation
- 2011-02-22 US US13/580,323 patent/US9457084B2/en active Active
- 2011-02-22 CN CN201711045618.XA patent/CN107693518A/zh active Pending
- 2011-02-22 WO PCT/JP2011/000994 patent/WO2011102149A1/en not_active Ceased
- 2011-02-22 JP JP2012538520A patent/JP6152643B2/ja active Active
- 2011-02-22 KR KR1020127024115A patent/KR101780666B1/ko active Active
- 2011-02-22 CN CN2011800104626A patent/CN102770159A/zh active Pending
- 2011-02-22 CA CA3009937A patent/CA3009937C/en active Active
- 2011-02-22 EP EP11744440.6A patent/EP2538978B1/en active Active
- 2011-02-22 RU RU2012140450/15A patent/RU2571816C2/ru active
- 2011-02-22 MX MX2012009503A patent/MX341482B/es active IP Right Grant
- 2011-02-22 ES ES11744440.6T patent/ES2600355T3/es active Active
- 2011-02-22 CA CA2789665A patent/CA2789665C/en active Active
-
2017
- 2017-01-27 JP JP2017013578A patent/JP2017095511A/ja not_active Withdrawn
-
2018
- 2018-06-15 HK HK18107808.7A patent/HK1249401A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2571816C2 (ru) | 2015-12-20 |
| CA2789665C (en) | 2020-06-16 |
| EP2538978A1 (en) | 2013-01-02 |
| CN102770159A (zh) | 2012-11-07 |
| MX341482B (es) | 2016-08-22 |
| CA3009937A1 (en) | 2011-08-25 |
| EP2538978B1 (en) | 2016-09-07 |
| HK1249401A1 (zh) | 2018-11-02 |
| BR112012020236A2 (pt) | 2016-05-17 |
| KR101780666B1 (ko) | 2017-09-21 |
| MX2012009503A (es) | 2012-09-12 |
| WO2011102149A1 (en) | 2011-08-25 |
| JP2017095511A (ja) | 2017-06-01 |
| CN107693518A (zh) | 2018-02-16 |
| JP2013520397A (ja) | 2013-06-06 |
| EP2538978A4 (en) | 2013-10-16 |
| KR20130040787A (ko) | 2013-04-24 |
| JP6152643B2 (ja) | 2017-06-28 |
| HK1178088A1 (zh) | 2013-09-06 |
| CA3009937C (en) | 2020-12-15 |
| RU2012140450A (ru) | 2014-03-27 |
| US20120316197A1 (en) | 2012-12-13 |
| US9457084B2 (en) | 2016-10-04 |
| CA2789665A1 (en) | 2011-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2600355T3 (es) | Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis | |
| ES2496092T3 (es) | El uso de amisulprida para tratar náuseas y vómitos posoperatorios | |
| ES2532948T3 (es) | Composición tópica para el tratamiento de queratosis actínica | |
| JO3187B1 (ar) | (4-(8- ميثوكسي بروبان -2-يل)-2-(تترا هيدرو - 2h - بيران-4-يل)- 1h - ايميدازو [ 4, 5- c ] كوينولين -7-يل)-3, 5- داي ميثيل ايزوكسازول واستخدامه كمثبط نطاق برومو | |
| UA113157C2 (xx) | Спосіб лікування з використанням селективних інгібіторів bcl-2 | |
| CL2014000492A1 (es) | Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras | |
| ECSP10010390A (es) | Compuestos | |
| BR112014030400A2 (pt) | formas sólidas de um composto antiviral | |
| BR112012012131A2 (pt) | uso de agonistas de receptores adrenérgicos alfa-2 para tratar ou prevenir psoríase | |
| ES2531274T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
| ECSP11011294A (es) | Compuestos de anillo fusionados y su uso | |
| UY34132A (es) | Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab. | |
| MX2017008150A (es) | Derivados de bencimidazol sulfonamidas como agonistas inversos del receptor gamma huerfano relacionado con el retinoide por gamma (t). | |
| EA201201081A1 (ru) | Производные гетарил[1,8]нафтиридина | |
| FR2894959B1 (fr) | Derives biphenyliques agonistes selectifs du recepteur rar-gamma | |
| EA200901619A1 (ru) | Способ получения телмисартана | |
| EA201401084A1 (ru) | Соли 5-[(1r)-2({2-[4-(2,2-дифтор-2-фенилэтокси)фенил]этил}амино)-1-гидроксиэтил]-8-гидроксихинолин-2(1н)-она | |
| BR112013033759A8 (pt) | Forma de dosagem unitária de um gel de base aquosa de metronidazol mucoadesivo e uso relacionado ao gel de base aquosa de metronidazol | |
| CY1119581T1 (el) | Παραγωγα πυριδινυλο- και πυραζινυλο-μεθυλοξυ-αρυλιου χρησιμα ως αναστολεις της τυροσινης κινασης σπληνας (syk) | |
| ES2633762T3 (es) | Hipertensión e hiperuricemia | |
| EP2803434A4 (en) | DEVICE AND METHOD FOR PROCESSING ANODLE PLATE FOR ELECTROLYSIS | |
| ME01516B (me) | DERIVAT DIBENZOTIAZEPINA l NJEGOVA UPOTREBA | |
| AR108389A2 (es) | Derivados de ácido fenilacético | |
| IL231820A0 (en) | Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors | |
| UY33263A (es) | Procedimiento para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida |